AMARIN CORP PLC\UK Payments for Restructuring
AMARIN CORP PLC\UK (AMRN) reported Payments for Restructuring of $8.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-07-29
- AMARIN CORP PLC\UK payments for restructuring for the quarter ending 2026-06-30 was $2.69M.
- AMARIN CORP PLC\UK payments for restructuring for the quarter ending 2026-03-31 was $5.47M.
- AMARIN CORP PLC\UK payments for restructuring for the quarter ending 2025-12-31 was $9.44M, a 4.72% decline year-over-year.
- AMARIN CORP PLC\UK payments for restructuring for the quarter ending 2024-12-31 was $9.90M, a 39.32% decline year-over-year.
- AMARIN CORP PLC\UK payments for restructuring for fiscal 2025 was $26.63M, a 95.93% increase from fiscal 2024.
- AMARIN CORP PLC\UK payments for restructuring for fiscal 2024 was $13.59M, a 64.09% decline from fiscal 2023.
- AMARIN CORP PLC\UK payments for restructuring for fiscal 2023 was $37.84M, a 14.00% increase from fiscal 2022.
- AMARIN CORP PLC\UK payments for restructuring for fiscal 2022 was $33.19M, a 171.48% increase from fiscal 2021.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $8.17M 10-Q · filed 2026-07-29 | $17.60M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2026-03-31 | $5.47M 10-Q · filed 2026-04-29 | $14.91M derived: sum of 2 quarters · filed 2026-04-29 | ||
| 2025-12-31 | $9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $26.63M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $17.19M 10-Q · filed 2025-10-29 | |||
| 2024-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $10.23M derived: sum of 2 quarters · filed 2025-03-12 | $10.71M derived: sum of 3 quarters · filed 2025-03-12 | $13.59M 10-K · filed 2025-03-12 |
| 2024-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $809.00K derived: sum of 2 quarters · filed 2024-10-30 | $3.69M 10-Q · filed 2024-10-30 | $20.01M derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-30 | $483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $3.36M 10-Q · filed 2024-07-31 | $19.68M derived: sum of 3 quarters · filed 2024-07-31 | $30.87M derived: sum of 4 quarters · filed 2024-07-31 |
| 2024-03-31 | $2.88M 10-Q · filed 2024-05-01 | $19.20M derived: sum of 2 quarters · filed 2024-05-01 | $30.39M derived: sum of 3 quarters · filed 2024-05-01 | $30.39M derived: sum of 4 quarters · filed 2024-05-01 |
| 2023-12-31 | $16.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $27.51M derived: sum of 2 quarters · filed 2024-02-29 | $27.51M derived: sum of 3 quarters · filed 2024-02-29 | $37.84M 10-K · filed 2024-02-29 |
| 2023-09-30 | $11.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $11.20M derived: sum of 2 quarters · filed 2023-11-01 | $21.52M 10-Q · filed 2023-11-01 | $27.09M derived: sum of 4 quarters · filed 2023-11-01 |
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $10.32M 10-Q · filed 2023-08-02 | $15.90M derived: sum of 3 quarters · filed 2023-08-02 | $39.58M derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | $10.32M 10-Q · filed 2023-05-03 | $15.90M derived: sum of 2 quarters · filed 2023-05-03 | $39.57M derived: sum of 3 quarters · filed 2023-05-03 | $42.56M derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $29.25M derived: sum of 2 quarters · filed 2023-03-01 | $32.24M derived: sum of 3 quarters · filed 2023-03-01 | $33.19M 10-K · filed 2023-03-01 |
| 2022-09-30 | $23.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $26.67M derived: sum of 2 quarters · filed 2022-10-27 | $27.61M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $3.94M 10-Q · filed 2022-08-03 | ||
| 2022-03-31 | $948.00K 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $12.22M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |